| |
|
|
Bukwang Pharmaceutical Co.,Ltd (003000) |
|
|
STOCK |
|
|
|
  |
(unit : Won, Share) |
| Fiscal Year End |
08.03 | 09.03 | 10.03 | 10.09 |
| Par Value |
500 | 500 | 500 | 500 |
| Yearly Highest Price |
40,300 | 35,000 | 22,050 | 18,800 |
| Yearly Lowest Price |
16,150 | 9,740 | 13,600 | 11,950 |
| Common Shares O/S |
25,759,460 | 27,045,225 | 27,045,225 | 27,045,225 |
| Preferred Shares O/S |
- | - | - | - |
| Market Cap.(100Mn.Won) |
8,371 | 5,665 | 4,367 | 3,407 |
| Dividends (%) |
C80.0/S5.0 | 60.0 | 100.0 | - |
|
 |
(Company/Sector/Market) |
| |
2009.06 | 2010.06 |
| Beta |
0.98 / 0.54 / 1.00 | 0.68 / 0.55 / 1.00 |
| Volatility |
72.82 / 32.47 / 41.28 | 38.35 / 20.53 / 17.70 |
|
 |
(unit : Won) |
| Fiscal Year End |
08.03 | 09.03 | 10.03 | 10.09 |
| Earnings Per Share |
1,296 | 1,174 | 1,056 | 796 |
| Sales Per Share |
6,139 | 6,143 | 6,473 | 6,433 |
| Book Value Per Share |
6,341 | 6,049 | 6,776 | 6,648 |
| Cash Flow Per Share |
1,043.17 | - 94.17 | 584.26 | 1,033.72 |
|
 |
(Unit : Times) |
| Fiscal Year End |
08.03 | 09.03 | 10.03 | 10.09 |
| Price / Earnings (H/L) |
31.10/12.46 | 29.81/8.30 | 20.88/12.88 | 23.62/15.01 |
| Price / Sales (H/L) |
6.56/2.63 | 5.70/1.59 | 3.41/2.10 | 2.92/1.86 |
| Price / Book (H/L) |
6.36/2.55 | 5.79/1.61 | 3.25/2.01 | 2.83/1.80 |
| Price / Cash Flow (H/L) |
38.63 / 15.48 | - /- | 37.74 / 23.28 | 18.19 / 11.56 |
|
 |
(Unit : 100Mn.Won, %) |
| Fiscal Year End |
07.03 |
08.03 |
09.03 |
10.03 |
| Company |
Sector |
Company |
Sector |
Company |
Sector |
Company |
Sector |
| Invested Capital |
1,162 |
708 |
1,217 |
940 |
1,368 |
1,048 |
1,688 |
- |
| NOPLAT |
182 |
60 |
295 |
70 |
311 |
143 |
397 |
- |
| Return on Invested Capital |
15 |
8 |
24 |
7 |
22 |
13 |
23 |
- |
| WACC |
7 |
6 |
7 |
6 |
7 |
6 |
- |
- |
| Economic Value Added |
90.7 |
10.9 |
207.4 |
5.3 |
205.9 |
75.1 |
- |
- |
|
 |
(Unit : 100Mn.Won, Times) |
| Fiscal Year End |
2008.03 | 2009.03 | 2010.03 | 2010.09 |
| Enterprise Value(EV) |
8,371.82 | 5,672.30 | 4,367.80 | 3,475.91 |
| EBITDA |
460.55 | 439.40 | 421.27 | 397.58 |
| EBITDA/Sales |
0.30 | 0.27 | 0.25 | 0.23 |
| EBITDA/Financial Exp. |
6,579,250.14 | 27.42 | 18.17 | 17.10 |
| EV/EBITDA |
18.18 | 12.91 | 10.37 | 8.74 |
|
|
|
|
